Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yau H, Kinaan M, Quinn SL, Moraitis AG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	octreotide octreotide LAR neuroendocrine tumor somatostatin analogue NETTER-1 PROMID RADIANT-2 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1d3c8f6693434240b731c33422227443
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d3c8f6693434240b731c33422227443
record_format	dspace
spelling	oai:doaj.org-article:1d3c8f6693434240b731c334222274432021-12-02T04:06:27ZOctreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives1177-5491https://doaj.org/article/1d3c8f6693434240b731c334222274432017-12-01T00:00:00Zhttps://www.dovepress.com/octreotide-long-acting-repeatable-in-the-treatment-of-neuroendocrine-t-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; 3Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA Abstract: Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide’s efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials. Keywords: carcinoid, everolimus, neuroendocrine tumor, octreotide LAR, somatostatin analog, ITMO, NETTER-1, PROMID, RADIANT-2Yau HKinaan MQuinn SLMoraitis AGDove Medical Pressarticleoctreotideoctreotide LARneuroendocrine tumorsomatostatin analogueNETTER-1PROMIDRADIANT-2Medicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 11, Pp 115-122 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	octreotide octreotide LAR neuroendocrine tumor somatostatin analogue NETTER-1 PROMID RADIANT-2 Medicine (General) R5-920
spellingShingle	octreotide octreotide LAR neuroendocrine tumor somatostatin analogue NETTER-1 PROMID RADIANT-2 Medicine (General) R5-920 Yau H Kinaan M Quinn SL Moraitis AG Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
description	Hanford Yau,1 Mustafa Kinaan,2 Suzanne L Quinn,3 Andreas G Moraitis3 1Division of Endocrinology, Diabetes, and Metabolism, University of California, San Francisco (Fresno Division), Fresno, CA, USA; 2Division of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USA; 3Division of Endocrinology, Diabetes, and Metabolism, Orlando VA Medical Center, Orlando, FL, USA Abstract: Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide’s efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials. Keywords: carcinoid, everolimus, neuroendocrine tumor, octreotide LAR, somatostatin analog, ITMO, NETTER-1, PROMID, RADIANT-2
format	article
author	Yau H Kinaan M Quinn SL Moraitis AG
author_facet	Yau H Kinaan M Quinn SL Moraitis AG
author_sort	Yau H
title	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
title_short	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
title_full	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
title_fullStr	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
title_full_unstemmed	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
title_sort	octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/1d3c8f6693434240b731c33422227443
work_keys_str_mv	AT yauh octreotidelongactingrepeatableinthetreatmentofneuroendocrinetumorspatientselectionandperspectives AT kinaanm octreotidelongactingrepeatableinthetreatmentofneuroendocrinetumorspatientselectionandperspectives AT quinnsl octreotidelongactingrepeatableinthetreatmentofneuroendocrinetumorspatientselectionandperspectives AT moraitisag octreotidelongactingrepeatableinthetreatmentofneuroendocrinetumorspatientselectionandperspectives
_version_	1718401417145745408

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Ejemplares similares